| Detected | Trial | Change |
|---|---|---|
| 2026-06-10 | NCT07468071 Rollover Study for Participants Who Have Been Treated With and Are Continuing to Benefit… |
Recruitment opened |
| 2026-06-09 | NCT06422520 A First-in-Human Study of BGB-C354 Alone and in Combination With Tislelizumab in… |
Trial completed |
| 2026-06-09 | NCT06422520 A First-in-Human Study of BGB-C354 Alone and in Combination With Tislelizumab in… |
Enrollment reduced: 120 -> 63 participants |
| 2026-06-09 | NCT06422520 A First-in-Human Study of BGB-C354 Alone and in Combination With Tislelizumab in… |
date change Primary completion moved earlier: 2026-12-01 -> 2026-05-15 |
| 2026-06-09 | NCT06422520 A First-in-Human Study of BGB-C354 Alone and in Combination With Tislelizumab in… |
date change Completion moved earlier: 2027-01-31 -> 2026-05-15 |
| 2026-06-05 | NCT06596473 A Study of BG-C477 in Participants With Advanced Solid Tumors |
Trial sites expanded: 49 -> 52 locations |
| 2026-06-04 | NCT06427941 A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without… |
Trial sites expanded: 29 -> 46 locations |
| 2026-06-04 | NCT04164199 Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With… |
Trial completed |
| 2026-06-04 | NCT04164199 Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With… |
date change Primary completion moved earlier: 2026-07 -> 2026-05-23 |
| 2026-06-04 | NCT04164199 Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With… |
date change Completion moved earlier: 2026-07 -> 2026-05-23 |
| 2026-06-04 | NCT06585488 A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in… |
Trial terminated — check why_stopped for reason |
| 2026-06-04 | NCT06585488 A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in… |
critical why stopped: null → "The Sponsor has made the decision to terminate this study due to the lack of promising efficacy, internal prioritization, and highly competitive landscape." |
| 2026-06-04 | NCT06585488 A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in… |
Enrollment reduced: 514 -> 47 participants |
| 2026-06-04 | NCT06585488 A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in… |
Sponsor changed: BeiGene -> BeOne Medicines |
| 2026-06-04 | NCT06585488 A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in… |
date change Primary completion moved earlier: 2026-12 -> 2026-04-23 |
| 2026-06-04 | NCT06585488 A First-in-human Study of BGB-53038, a Pan-KRAS Inhibitor, Alone or in Combinations in… |
date change Completion moved earlier: 2026-12 -> 2026-04-23 |
| 2026-05-30 | NCT07043400 A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus… |
Trial sites expanded: 86 -> 93 locations |
| 2026-05-28 | NCT07414836 A First-in-Human Study of BG-C0979 in Adults With Advanced Solid Tumors |
Trial sites expanded: 4 -> 8 locations |
| 2026-05-27 | NCT06596473 A Study of BG-C477 in Participants With Advanced Solid Tumors |
Trial sites expanded: 41 -> 49 locations |
| 2026-05-15 | NCT06427941 A Phase 1 Study of BGB-B2033, Alone or in Combination With Tislelizumab With or Without… |
Primary endpoint(s) modified |
| First Posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-06-08 | NCT07633873 SYS6010 Combined With Enlonstobart Versus Immunotherapy+ Platinum-based Chemotherapy for… | Phase 3 | Not Yet Recruiting |
| 2026-05-27 | NCT07609121 Hypofractionated Chemoradiotherapy With Tislelizumab and Surufatinib for Unresectable… | Phase 2 | Not Yet Recruiting |
| 2026-05-27 | NCT07609667 SKB315 in Combination Therapy in Patients With Advanced or Metastatic GC/ GEJ… | Phase 2 | Not Yet Recruiting |
| 2026-05-22 | NCT07601737 Nimotuzumab Combined With PD-1 Inhibitors and Chemotherapy in the Treatment of Locally… | Phase 2 | Recruiting |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 3 | |||
| NCT07315750 | A Study of Disitamab Vedotin Combined With Trastuzumab and Tislelizumab Versus… | Gastric Carcinoma | Recruiting |
| NCT06745908 | Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and… | NSCLC Stage IV | Recruiting |
| NCT07043400 | A Study to Investigate Tislelizumab Administered as Subcutaneous Injection Versus… | Metastatic Gastric Adenocarcinoma | Recruiting |
| NCT06206733 | ASKB589 in Combination With CAPOX and PD-1 Inhibitor in Patients With Advanced or… | Gastroesophageal Junction Adenocarcinoma | Active, Not Recruiting |
| NCT07373990 | Short-course Tislelizumab Combined With Chemoradiotherapy for Nasopharyngeal Carcinoma | Nasopharyngeal Cancinoma (NPC) | Not Yet Recruiting |
| NCT07383116 | Phase III Clinical Study of HB0025 Combined With Chemotherapy Versus Tislelizumab… | Non Squamous Non-small Cell Lung Cancer | Not Yet Recruiting |
| NCT07385703 | Clinical Study on the Efficacy and Safety of LM-302 Injection Combined With Tislelizumab… | Adenocarcinoma | Not Yet Recruiting |
| NCT07475026 | A Study of Neoadjuvant Tislelizumab Plus Lenvatinib in Resectable HCC at High Risk of… | HCC - Hepatocellular Carcinoma | Not Yet Recruiting |
| NCT04379635 | Comparing the Efficacy and Safety of a New Additional Treatment With Tislelizumab in… | Non Small Cell Lung Cancer | Active, Not Recruiting |
| NCT07502300 | A Study Comparing BL-B01D1 Combined With Tislelizumab Versus Platinum-containing… | Extensive-stage Small-cell Lung Cancer | Not Yet Recruiting |
| NCT03967977 | Study of Tislelizumab in Combination With Chemotherapy Compared to Chemotherapy Alone for… | Urothelial Carcinoma | Active, Not Recruiting |
| NCT05152147 | A Study of Zanidatamab in Combination With Chemotherapy Plus or Minus Tislelizumab in… | Gastric Neoplasms | Active, Not Recruiting |
| NCT05211232 | Neoadjuvant and Adjuvant Tislelizumab for Nasopharyngeal Carcinoma | Nasopharyngeal Carcinoma | Active, Not Recruiting |
| NCT06914011 | Circulating Tumor DNA MRD-Guided Adjuvant Therapy for Curatively Resected Locally… | Esophageal Cancer | Not Yet Recruiting |
| NCT07633873 | SYS6010 Combined With Enlonstobart Versus Immunotherapy+ Platinum-based Chemotherapy for… | Non-Small Cell Lung Cancer | Not Yet Recruiting |
| Phase 2/3 | |||
| NCT06312982 | A Series of Neoadjuvant Chemoradiotherapy Combined With Immunotherapy for Locally… | Locally Advanced Rectal Carcinoma | Recruiting |
| NCT06563245 | Brentuximab Vedotin for Newly Diagnosed cHL in Chinese CAYA Based on PET/CT Assessment | Classical Hodgkin Lymphoma | Recruiting |
| NCT07554456 | A Study of BL-B01D1 in Combination With Tislelizumab ±5-Fluorouracil Versus… | Esophageal Squamous Cell Carcinoma | Not Yet Recruiting |
| Phase 2 | |||
| NCT07050056 | Tislelizumab Combined With Thoracic Radiotherapy as Neoadjuvant Therapy for Resectable… | Resectable NSCLC | Recruiting |
| NCT07330037 | TALENT Study: Phase II Trial of Adjuvant L-TIL Plus Tislelizumab in Resectable NSCLC… | NSCLC | Recruiting |
| NCT05366829 | Tislelizumab Consolidation After Liver-Directed Therapy for Hepatocellular Carcinoma | Carcinoma, Hepatocellular | Recruiting |
| NCT06764355 | Neoadjuvant Immunochemotherapy and Chemoradiotherapy Followed by Surgery for Advanced… | ESCC | Recruiting |
| NCT07370337 | Induction Chemotherapy Combined With Tislelizumab for Locally Advanced Squamous Cell… | Squamous Cell Carcinoma of External Auditory Canal | Recruiting |
| NCT07039162 | Study of Tislelizumab Combined With Chemoradiotherapy and Surgery for Unresectable… | Esophageal Squamous Cell Carcinoma (ESCC) | Recruiting |
| NCT07120282 | Study to Evaluate the Efficacy and Safety of Adjuvant Tislelizumab in High-Risk Stage I… | Lung Cancer (NSCLC) | Recruiting |